{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open+Label+Extension+Study&page=52", "query": { "intervention": "Open Label Extension Study", "page": 52 }, "page_size": 10 }, "pagination": { "page": 52, "page_size": 10, "total_count": 2084, "total_pages": 209, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open+Label+Extension+Study&page=53&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open+Label+Extension+Study&page=51&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-05T17:16:23.936Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04338022", "title": "Study of Evobrutinib in Participants With RMS (evolutionRMS 1)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsing Multiple Sclerosis" ], "interventions": [ { "name": "Teriflunomide", "type": "DRUG" }, { "name": "Evobrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 1124, "start_date": "2020-06-12", "completion_date": "2024-03-08", "has_results": true, "last_update_posted_date": "2025-06-12", "last_synced_at": "2026-11-05T17:16:23.936Z", "location_count": 51, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Long Beach, California + 44 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Long Beach", "state": "California" }, { "city": "Pasadena", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04338022" }, { "nct_id": "NCT07670702", "title": "An Evaluation of the Long-Term Safety and Efficacy of TSND-201 for the Treatment of PTSD", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Post Traumatic Stress Disorder" ], "interventions": [ { "name": "TSND-201", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Transcend Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 300, "start_date": "2026-06-22", "completion_date": "2029-01", "has_results": false, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-11-05T17:16:23.936Z", "location_count": 17, "location_summary": "Little Rock, Arkansas • Los Angeles, California • Montclair, California + 14 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Montclair", "state": "California" }, { "city": "Evergreen", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07670702" }, { "nct_id": "NCT04033367", "title": "SAR231893-LPS15497- \"Dupilumab Effect on Sleep in AD Patients\"", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Dupilumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 188, "start_date": "2019-08-22", "completion_date": "2021-10-06", "has_results": true, "last_update_posted_date": "2025-09-17", "last_synced_at": "2026-11-05T17:16:23.936Z", "location_count": 8, "location_summary": "North Little Rock, Arkansas • Redwood City, California • Rolling Hills Estates, California + 5 more", "locations": [ { "city": "North Little Rock", "state": "Arkansas" }, { "city": "Redwood City", "state": "California" }, { "city": "Rolling Hills Estates", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04033367" }, { "nct_id": "NCT05066698", "title": "ST266 Eyedrops for the Treatment of Persistent Corneal Epithelial Defects", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Persistent Corneal Epithelial Defect" ], "interventions": [ { "name": "ST266", "type": "BIOLOGICAL" }, { "name": "0.67% Sodium Chloride Ophthalmic Solution", "type": "OTHER" }, { "name": "Open-label ST266", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Noveome Biotherapeutics, formerly Stemnion", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2022-04-27", "completion_date": "2022-09-07", "has_results": false, "last_update_posted_date": "2022-10-25", "last_synced_at": "2026-11-05T17:16:23.936Z", "location_count": 31, "location_summary": "Dothan, Alabama • Little Rock, Arkansas • Huntington Beach, California + 23 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05066698" }, { "nct_id": "NCT00607919", "title": "Treatment of ADHD With Atomoxetine in Children & Adolescents With ADHD & Comorbid Dyslexia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Attention Deficit Hyperactivity Disorder", "Dyslexia" ], "interventions": [ { "name": "Atomoxetine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": "16 Years", "sex": "ALL", "summary": "10 Years to 16 Years" }, "enrollment_count": 209, "start_date": "2008-03", "completion_date": "2011-02", "has_results": true, "last_update_posted_date": "2011-12-15", "last_synced_at": "2026-11-05T17:16:23.936Z", "location_count": 16, "location_summary": "Irvine, California • Palo Alto, California • San Francisco, California + 13 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00607919" }, { "nct_id": "NCT01226472", "title": "Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Peripheral T-cell Lymphoma", "Cutaneous T-cell Lymphoma" ], "interventions": [ { "name": "KW-0761", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Kyowa Kirin Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2010-08", "completion_date": "2012-09", "has_results": true, "last_update_posted_date": "2024-04-25", "last_synced_at": "2026-11-05T17:16:23.936Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01226472" }, { "nct_id": "NCT04143217", "title": "Open-label Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Attention-Deficit/Hyperactivity Disorder" ], "interventions": [ { "name": "SPN-812", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Supernus Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 159, "start_date": "2020-01-23", "completion_date": "2022-12-14", "has_results": true, "last_update_posted_date": "2024-02-13", "last_synced_at": "2026-11-05T17:16:23.936Z", "location_count": 38, "location_summary": "Beverly Hills, California • Garden Grove, California • Los Alamitos, California + 33 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Garden Grove", "state": "California" }, { "city": "Los Alamitos", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Riverside", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04143217" }, { "nct_id": "NCT00081497", "title": "A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Fabry Disease" ], "interventions": [ { "name": "agalsidase beta", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Genzyme, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 67, "start_date": "2004-01", "completion_date": "2005-09", "has_results": true, "last_update_posted_date": "2015-04-02", "last_synced_at": "2026-11-05T17:16:23.936Z", "location_count": 18, "location_summary": "Birmingham, Alabama • Los Angeles, California • San Francisco, California + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "West Hartford", "state": "Connecticut" }, { "city": "Coral Springs", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00081497" }, { "nct_id": "NCT00891046", "title": "An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Systemic Juvenile Idiopathic Arthritis" ], "interventions": [ { "name": "Canakinumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "19 Years", "sex": "ALL", "summary": "2 Years to 19 Years" }, "enrollment_count": 270, "start_date": "2009-09", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2019-03-26", "last_synced_at": "2026-11-05T17:16:23.936Z", "location_count": 6, "location_summary": "Los Angeles, California • Louisville, Kentucky • Boston, Massachusetts + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00891046" }, { "nct_id": "NCT02421679", "title": "Open Label Extension Safety and Efficacy Study of TNX-102 SL Tablets in Military Related PTSD and Related Conditions", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "PTSD" ], "interventions": [ { "name": "TNX-102 SL", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tonix Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 159, "start_date": "2015-04-14", "completion_date": "2016-05-26", "has_results": true, "last_update_posted_date": "2025-02-06", "last_synced_at": "2026-11-05T17:16:23.936Z", "location_count": 22, "location_summary": "Tuscaloosa, Alabama • Phoenix, Arizona • Imperial, California + 19 more", "locations": [ { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Imperial", "state": "California" }, { "city": "National City", "state": "California" }, { "city": "Oceanside", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02421679" } ] }